Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: A single-center experience

Transplant Immunology

Volumn 29, Issue 1-4, 2013, Pages 7-10

  Cicora, Federico ^a,b   Paz, Marta ^a   Mos, Fernando ^a   Roberti, Javier ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b Foundation for Research and Assistance in Kidney Disease (FINAER)   (Argentina)

Author keywords

Alloantibody; Bortezomib; HLA; Kidney; Proteasome inhibitor; Transplantation

Indexed keywords

BASILIXIMAB; BORTEZOMIB; CORTICOSTEROID; CREATININE; EVEROLIMUS; HLA ANTIBODY; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; FEMALE; GLOMERULOPATHY; HUMAN; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; MIDDLE AGED; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTE COUNT; TUBULAR ATROPHY; VIRUS PNEUMONIA;

ALLOANTIBODY; BORTEZOMIB; HLA; KIDNEY; PROTEASOME INHIBITOR; TRANSPLANTATION;

ADULT; ALLOGRAFTS; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; BORONIC ACIDS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PYRAZINES;

EID: 84897075108     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.08.003     Document Type: Article

References (16)

1. Lemy A., Toungouz M., Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization?. Nephrol. Dial. Transplant. 2010, 25(11):3480-3489.
2. Everly M.J., Terasaki P.I., Trivedi H.L. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012, 93(6):572-577.
3. Roberts D.M., Jiang S.H., Chadban S.J. The treatment of acute antibody-mediated rejection in kidney transplant recipients - a systematic review. Transplantation 2012, 94(8):775-783.
4. Kute V.B., Vanikar A.V., Trivedi H.L., Shah P.R., Goplani K.R. Desensitization protocol for highly sensitized renal transplant. Saudi J. Kidney Dis. Transpl. 2011, 22(4):662-669.
5. Walsh R.C., Everly J.J., Brailey P., Rike A.H., Arend L.J., Mogilishetty G., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89(3):277-284.
6. Trivedi H.L., Terasaki P.I., Feroz A., Everly M.J., Vanikar A.V., Shankar V., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87(10):1555-1561.
7. Walsh R.C., Alloway R.R., Girnita A.L., Woodle E.S. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012, 81(11):1067-1074.
8. Nigos J.G., Arora S., Nath P., Hussain S.M., Marcus R.J., Ko T.Y., et al. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen. Exp. Clin. Transplant. 2012, 10(6):609-613.
9. Perry D.K., Burns J.M., Pollinger H.S., Amiot B.P., Gloor J.M., Gores G.J., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 2009, 9(1):201-209.
10. Schmidt N., Alloway R.R., Walsh R.C., Sadaka B., Shields A.R., Girnita A.L., et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 2012, 94(4):352-361.
11. Sberro-Soussan R., Zuber J., Suberbielle-Boissel C., Candon S., Martinez F., Snanoudj R., et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am. J. Transplant. 2010, 10(3):681-686.
12. Everly M.J., Everly J.J., Susskind B., Brailey P., Arend L.J., Alloway R.R., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86(12):1754-1761.
13. Vanikar A., Trivedi V.B., Khemchandani S.I., Modi P.R., Kaneku H., Idica A.K., et al. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation 2010, 90(2):220-221.
14. Walsh R.C., Brailey P., Girnita A., Alloway R.R., Shields A.R., Wall G.E., et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011, 91(11):1218-1226.
15. Wiebe C., Gibson I.W., Blydt-Hansen T.D., Karpinski M., Ho J., Storsley L.J., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 2012, 12(5):1157-1167.
16. Flechner S.M., Fatica R., Askar M., Stephany B.R., Poggio E., Koo A., et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90(12):1486-1492.